Corixa psoriasis deal with Medicis

CRXA granted MRX exclusive commercialization and distribution rights in the U.S. and Canada its Phase II psoriasis immunotherapeutic PVAC, a heat-killed extract of Mycobacterium vaccae. CRXA will deve...